Case Reports in Hepatology最新文献_第4页

A Case of a Large Intraabdominal Abscess in a Patient with Cirrhosis Misdiagnosed as Spontaneous Bacterial Peritonitis. 肝硬化大腹内脓肿误诊为自发性细菌性腹膜炎1例。

Case Reports in Hepatology Pub Date : 2022-10-05 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5951115

Saeed Ali, Abdullah Sohail, Kyle Brown

{"title":"A Case of a Large Intraabdominal Abscess in a Patient with Cirrhosis Misdiagnosed as Spontaneous Bacterial Peritonitis.","authors":"Saeed Ali, Abdullah Sohail, Kyle Brown","doi":"10.1155/2022/5951115","DOIUrl":"https://doi.org/10.1155/2022/5951115","url":null,"abstract":"Spontaneous bacterial peritonitis is a known complication of patients with decompensated cirrhosis and ascites. It is differentiated from secondary bacterial peritonitis by the absence of an intraabdominal source of infection. We present a 56-year-old man with alcoholic cirrhosis who underwent multiple paracenteses that yielded fluid with progressively increasing neutrophil counts and several different organisms, recurring despite numerous treatments for SBP. Eventually, a computed tomography (CT) of the abdomen and the pelvis revealed a large intraabdominal abscess (22 × 13 cm) treated with an ultrasound-guided drain and IV antibiotics. Recurrent episodes of SBP despite appropriate antibiotics should raise suspicion for secondary bacterial peritonitis. It is crucial to differentiate SBP from secondary bacterial peritonitis as the mortality of the latter is much higher without prompt treatment. Appropriate antibiotic regimens, prompt surgical treatment, and postoperative care are crucial to improving clinical outcomes in these patients.","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":" ","pages":"5951115"},"PeriodicalIF":0.0,"publicationDate":"2022-10-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33513482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma. Lenvatinib治疗肝癌诱导的肾病综合征。

Case Reports in Hepatology Pub Date : 2022-09-05 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5101856

Thaninee Prasoppokakorn, Kessarin Thanapirom, Sombat Treeprasertsuk

{"title":"Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma.","authors":"Thaninee Prasoppokakorn, Kessarin Thanapirom, Sombat Treeprasertsuk","doi":"10.1155/2022/5101856","DOIUrl":"https://doi.org/10.1155/2022/5101856","url":null,"abstract":"Lenvatinib, an oral small-molecule multiple tyrosine kinase inhibitor (TKI), has been approved for first-line therapy for unresectable hepatocellular carcinoma (HCC). Proteinuria is one of the most common adverse events associated with lenvatinib treatment. We reported a 67-year-old Thai female was diagnosed with NASH cirrhosis and HCC BCLC B with TACE refractoriness. She received 8 mg of lenvatinib for 2 weeks and began to experience worsening hypertension, bilateral pleural effusion, pedal edema, hypoalbuminemia, hypercholesterolemia, and proteinuria. After exclusion of all possible causes, lenvatinib-induced nephrotic syndrome (NS) was diagnosed. One week after discontinuing the drug, her symptoms gradually improved. To date, there have been only a handful of reported cases of lenvatinib-induced nephrotoxicity. We report herein the case of lenvatinib-induced NS in a cirrhotic patient with HCC with resolution of symptoms in a short period after drug discontinuation. In addition, we reviewed all reported cases of lenvatinib-induced nephrotoxicity.","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":" ","pages":"5101856"},"PeriodicalIF":0.0,"publicationDate":"2022-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9467805/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40360200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

IgG4-Related Hepatic Pseudotumor Masquerading as a Klatskin Tumor. igg4相关的肝假瘤伪装成克拉特皮瘤。

Case Reports in Hepatology Pub Date : 2022-06-28 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5765116

Jennifer Yoon, Steve Hu, Daniel Phillips, Amir Fathi, Adnan Ameer

引用次数: 1

A Case of Delayed Hepatic Injury Associated with Teriflunomide Use as Assessed for Causality Using the Updated RUCAM. 使用更新的RUCAM评估与特立氟米特相关的迟发性肝损伤1例

Case Reports in Hepatology Pub Date : 2022-06-15 eCollection Date: 2022-01-01 DOI: 10.1155/2022/6331923

Riana Wurzburger

引用次数: 4

Postliver Transplantation Rhino-Orbital Mucormycosis, an Unexpected Cause of a Downhill Course 肝移植后鼻-眶毛霉菌病，一个意想不到的下坡过程的原因

Case Reports in Hepatology Pub Date : 2022-05-28 DOI: 10.1155/2022/5413315

Swapnali Sabhapandit, Mithun Sharma, A. Sekaran, B. Menon, A. Kulkarni, Soumya Tr, P. Nagaraja Rao, D. Nageshwar Reddy

引用次数: 1

A Rare Cause of Haemorrhagic Shock: Rupture of Gastric Wall Seeding of Hepatocellular Carcinoma. 出血性休克的罕见病因:肝细胞癌胃壁破裂。

Case Reports in Hepatology Pub Date : 2022-03-12 eCollection Date: 2022-01-01 DOI: 10.1155/2022/6560834

Naoki Ishimaru, Hirohisa Fujikawa, Kazuya Niwa, Yoshifumi Kobayashi

引用次数: 0

Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review. 难治性丙型肝炎病毒感染1例报告及文献复习。

Case Reports in Hepatology Pub Date : 2022-03-11 eCollection Date: 2022-01-01 DOI: 10.1155/2022/3556780

Victoria Green, Marina Roytman

{"title":"Treatment-Resistant Hepatitis C Viral Infection: A Case Report and Literature Review.","authors":"Victoria Green, Marina Roytman","doi":"10.1155/2022/3556780","DOIUrl":"https://doi.org/10.1155/2022/3556780","url":null,"abstract":"Hepatitis C virus (HCV) is an ongoing global public health threat affecting millions worldwide. Increasing recognition of its impact and recent advances towards HCV prevention and cure have provided incentive for the World Health Organization to call for global elimination by 2030. The goal of therapy is to achieve a sustained virologic response (SVR-12), defined as undetectable HCV-RNA within 12 weeks after treatment completion. In 2011, approval was given for the first direct-acting antiviral agents (DAAs). More recently, in 2013, more effective DAAs, with pan-genomic properties, have been introduced, and these regimens boast increasing rates of SVR. The ultimate goal is that the history of HCV ends with the pan-genotypic efficacy of multiple, easy-to-use and tolerate, combination regimens. These regimens have already demonstrated the ability to cure previously challenging patient groups. However, limitations exist in the current portfolio of agents, with suboptimal outcomes for patients with HCV genotype 3. In addition to this, access to DAAs remains an obstacle for many patients. We present this case of a 61-year-old male with HCV genotype 3 who has had several treatment failures with standard HCV therapy who was eventually approved for compassionate use of a 16-week course of glecaprevir (GLE)/pibrentasvir (PIB), sofosbuvir (SOF), and ribavirin (RBV) which ultimately led to SVR-12.","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":" ","pages":"3556780"},"PeriodicalIF":0.0,"publicationDate":"2022-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933098/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40308782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Possible Paternal Hepatitis B Virus Infection with Different Clinical Courses between Siblings: A Report of Two Cases 兄弟姐妹之间可能存在的不同临床病程的父亲乙型肝炎病毒感染:两例报告

Case Reports in Hepatology Pub Date : 2022-03-07 DOI: 10.1155/2022/5812135

Y. Sasaki, H. Kajino

引用次数: 1

Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation. 血浆置换治疗鳞状细胞癌和既往原位肝移植患者的肝炎。

Case Reports in Hepatology Pub Date : 2022-01-21 eCollection Date: 2022-01-01 DOI: 10.1155/2022/5908411

Sanaa Al-Nattah, Kusum Lata Sharma, Matthew Caldis, Erin Spengler, William Nicholas Rose

{"title":"Plasmapheresis for Pembrolizumab-Induced Hepatitis in a Patient with Squamous Cell Carcinoma and Prior Orthotopic Liver Transplantation.","authors":"Sanaa Al-Nattah, Kusum Lata Sharma, Matthew Caldis, Erin Spengler, William Nicholas Rose","doi":"10.1155/2022/5908411","DOIUrl":"https://doi.org/10.1155/2022/5908411","url":null,"abstract":"Checkpoint inhibitor therapy with monoclonal antibodies against programmed cell death protein 1 (PD1) has been implemented in the treatment of numerous malignancies. Pembrolizumab is one such medication. While severe toxicities are very rare, mild immune-mediated reactions with a variety of end organ injuries are among the most commonly encountered adverse events attributed to these medications. Acute liver injury manifesting as biochemical abnormalities with or without synthetic dysfunction is one such potential adverse reaction. Rarely, a relatively severe hepatitis can occur. While such severe adverse events are often successfully managed with systemic corticosteroids and drug discontinuation, our patient was refractory to standard management. We present a case of pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation. Through a combination of serial plasmapheresis and intravenous immunoglobulin(IVIG) infusion, the patient's hepatitis resolved as evidenced by virtual normalization of his liver indices. This illustrates the effectiveness of a relatively novel treatment strategy for this rare side effect of checkpoint inhibitor antineoplastic therapy.","PeriodicalId":30295,"journal":{"name":"Case Reports in Hepatology","volume":" ","pages":"5908411"},"PeriodicalIF":0.0,"publicationDate":"2022-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799356/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39872123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Escalation to Barbiturate-Induced Coma for Refractory Seizures after Liver Transplantation. 肝移植后顽固性癫痫发作升级至巴比妥酸盐诱导昏迷。

Case Reports in Hepatology Pub Date : 2022-01-10 eCollection Date: 2022-01-01 DOI: 10.1155/2022/9311922

Brittany Miles, Muhammad Mujtaba, Shehzad Merwat, Rupak Kulkarni, Jeffrey Fair, Michael Kueht

引用次数: 0